Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Rehabilitation Group Significantly Reduces Fatigue-Related Stress

August 1, 2001
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 8
Volume 10
Issue 8

TAMPA, Florida-A rehabilitation group program-Energy for Living With Cancer-has the ability to reduce fatigue-related distress and improve quality of life, according to program developer Sandra Holley, PhD, ARNP, a nurse scientist at the James A. Haley Veterans Administration Medical Center, Tampa. Dr. Holley presented her results in a poster session at the Oncology Nursing Society’s 26th Annual Congress.

TAMPA, Florida—A rehabilitation group program—Energy for Living With Cancer—has the ability to reduce fatigue-related distress and improve quality of life, according to program developer Sandra Holley, PhD, ARNP, a nurse scientist at the James A. Haley Veterans Administration Medical Center, Tampa. Dr. Holley presented her results in a poster session at the Oncology Nursing Society’s 26th Annual Congress.

The Energy for Living With Cancer program is a structured rehabilitation intervention designed to educate patients about cancer-related fatigue and to provide support and sharing among participants. Patients meet for 90 minutes once a week for 8 weeks.

The education component covers topics such as risk factors for fatigue, how fatigue affects daily living, and fatigue management strategies. In the sharing and support component, patients relay their experiences, share coping techniques, and provide emotional support for one another.

To test the effectiveness of the program, Dr. Holley conducted a prospective pre/post-test study involving 20 program participants. The mean age of the participants was 63.6 (range, 38 to 86). Six different types of cancer were represented, and 15 of the patients were receiving cancer therapy at the time.

At the start of the program, study participants completed the Cancer-Related Fatigue Distress Scale, the Center for Epidemiological Studies—Depression form, and the Functional Living Index—Cancer scale. Upon study completion, participants re-took the tests and completed a program rating form.

Program rating results indicated a high degree of patient satisfaction with the program. On a scale of 0 to 10, the mean rating in the program evaluation was 9.8. Patients indicated that the educational topics were relevant and beneficial and that the 8-week fatigue-management intervention provided much-needed information and emotional support.

Moreover, post-program test results showed significant improvements in fatigue-related distress and quality of life. Fatigue distress scores decreased from a mean of 192.95 to 145.45, and quality-of-life scores increased from 98.65 to 145.45—nearly a 50% improvement. Depression scores decreased from 24.05 to 21.0, but this difference was not statistically significant.

Dr. Holley said that these preliminary findings indicate that the Energy for Living With Cancer program is appropriate and beneficial for cancer patients experiencing fatigue, even for those who are quite debilitated.

Articles in this issue

Amifostine Can Reduce Xerostomia, Loss of Taste, Fibrosis, and Pain
Three-Dimensional Conformal Radiation Therapy Reduces Rectal Damage in Prostate Cancer Treatment
Can Concurrent Amifostine and 5-FU Permit Delivery of Higher Boost Doses of Radiation?
Preventing Severe Esophagitis Critical in Chemoradiotherapy for Lung Cancer
Upcoming Trial to Test Ability of Amifostine to Reduce Radiation-Induced Hypothyroidism
Amifostine Offers Little Advantage in Small Trial of Twice-Daily Radiation Plus Chemotherapy
Subcutaneous Amifostine Provides Protection Against Radiation-Induced Acute Xerostomia
Study to Test Amifostine in Cervical Cancer Patients Treated With Combined-Modality Therapy
Radioprotectants May Extend Use of Combined Chemotherapy and Radiation
Amifostine Ameliorates Pneumonitis and Esophagitis During Radiochemotherapy
Potentially Useful Predictors of Risk for Developing Postradiation Pneumonitis
Amifostine Trial Represents First FDA Approval of Treatment Interacting With Radiation
Amifostine Reduces Side Effects During Treatment for Advanced Lung Cancer
Intrarectal Amifostine Prevents Late Rectal Complications of Radiotherapy for Prostate Cancer
Experts Consider Statistical Issues in Designing Studies of Toxicity Modifiers

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
2 experts in this video
Related Content

16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity

16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity

Yolcar Chamorro;Ana Sandoval Leon, MD;Cynthia Thiry;Barbara Gallo;Sherine Mitchell;Alejandro Larios Venegas
July 2nd 2025
Article

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.

3 Things You Should Know About Targeting NRG1 and Rare Drivers in Pancreatic Cancer

ONCOLOGY Staff
July 2nd 2025
Article

Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.


Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Roman Fabbricatore
July 2nd 2025
Article

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Related Content

16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity

16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity

Yolcar Chamorro;Ana Sandoval Leon, MD;Cynthia Thiry;Barbara Gallo;Sherine Mitchell;Alejandro Larios Venegas
July 2nd 2025
Article

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.

3 Things You Should Know About Targeting NRG1 and Rare Drivers in Pancreatic Cancer

ONCOLOGY Staff
July 2nd 2025
Article

Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.


Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Roman Fabbricatore
July 2nd 2025
Article

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.